Clinical Trials
21 trialsNCT03737981 2026-05-29
Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT02275533 2026-05-28
Testing Nivolumab to Prevent Disease From Coming Back After Treatment in Patients With Acute Myeloid Leukemia, REMAIN Trial
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06249880 2026-03-09
Pediatric Normative Markerless Movement Analysis
MultiCare Health System Research Institute
Recruiting
NCT03516617 2026-02-09
Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Mayo Clinic
Phase 2 Recruiting
NCT03059485 2026-02-04
DC/AML Fusion Cell Vaccine vs Observation in Patients Who Achieve a Chemotherapy-induced Remission
Beth Israel Deaconess Medical Center
Phase 2 Active not recruiting
NCT04229979 2025-10-01
REGAL
Sellas Life Sciences Group
Phase 3 Active not recruiting
NCT07035938 2025-07-23
T-cell Developmental Status in Patients With Malignant Hematological Tumors
The First Affiliated Hospital of Xiamen University
Recruiting
NCT05179824 2025-05-06
Tempus Priority Study: A Pan-tumor Observational Study
Tempus AI
Active not recruiting
NCT02085408 2024-12-13
Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Eastern Cooperative Oncology Group
Phase 3 Completed
NCT00877214 2024-08-22
MAINTAIN
University of Giessen
Phase 3 Active not recruiting
NCT06084923 2024-04-10
Outcomes of Unfit Patients With CLL Included in the GIMEMA LLC1114 Trial Who Discontinued Ibrutinib Due to Reasons Other Than Disease Progression
Gruppo Italiano Malattie EMatologiche dell'Adulto
Unknown
NCT05729178 2024-03-25
Unravelling the Role of KCTD Protein Family in the Clinical Management of Childhood Acute Lymphoblastic Leukemias
IRCCS SYNLAB SDN
Unknown
NCT00093470 2024-03-20
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
National Cancer Institute (NCI)
Phase 3 Completed
NCT04644419 2023-05-06
Chemotherapy-related Cognitive Impairment and Acute Leukemia
UNC Lineberger Comprehensive Cancer Center
Completed
NCT04638595 2022-08-05
Pediatric Normative Movement Analysis Data Collection
MultiCare Health System Research Institute
Completed
NCT01039376 2019-07-30
PROLONG
Novartis
Phase 3 Terminated
NCT01855698 2018-03-22
PENELOPE Observational Study: Prophylaxis and Treatment of Arterial and Venous Thromboembolism
Gruppo Italiano Malattie EMatologiche dell'Adulto
Completed
NCT00085709 2015-09-30
S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML
SWOG Cancer Research Network
Phase 3 Completed
NCT00411281 2015-09-30
Low-Dose Cytarabine in Treating Infants With Down Syndrome and Transient Myeloproliferative Disorder
Children's Oncology Group
Phase 3 Withdrawn
NCT00445731 2014-09-08
A Structured Walking Program or Standard Therapy in Cancer Patients Undergoing a Donor Bone Marrow Transplant
University of Minnesota
Phase NA Completed
NCT00006363 2013-06-04
Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 3 Completed